Previous Close | 60.98 |
1-Year Change | 52.49% |
6-Months Change | 11.24% |
3-Months Change | 2.75% |
Moving Avg (50d) | 59.816 |
Moving Avg (200d) | 57.834 |
ESG Rating | - |
Exchange | NYSE |
Market Cap. | 11.0B |
Beta (3-Years) | 1.1 |
Revenue Growth (ttm) | 2.77% |
Net Profit Margin (ttm) | -23.81% |
Return On Assets (ttm) | -10.69% |
EPS (ttm) | -5.77 |
PE Ratio (ttm) | -10.57 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Pharmaceuticals |
Country: | United States |
Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue. Catalent was formed... Wikipedia